|1.||de Oliveira-Fusaro, M C G: 1 article (09/2014)|
|2.||Parada, C A: 1 article (09/2014)|
|3.||Teixeira, J M: 1 article (09/2014)|
|4.||Tambeli, C H: 1 article (09/2014)|
|5.||Abdel-Rahman, Abdel A: 1 article (01/2011)|
|6.||El-Mas, Mahmoud M: 1 article (01/2011)|
|7.||Donovan, Shane: 1 article (10/2010)|
|8.||Campbell, Jennifer: 1 article (10/2010)|
|9.||Cammack, Jon: 1 article (10/2010)|
|10.||Nordhaus, Mark: 1 article (10/2010)|
01/01/2000 - "Bradyzide shows long-lasting oral activity in rodent models of inflammatory hyperalgesia, reversing Freund's complete adjuvant (FCA)-induced mechanical hyperalgesia in the rat knee joint (ED(50), 0.84 micromol kg(-1); duration of action >4 h). "
07/01/2007 - "Calotropis procera latex-induced inflammatory hyperalgesia - effect of bradyzide and morphine."
01/01/2000 - "Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia."
07/01/2007 - "2 The aim of the present study was to evaluate the anti-oedematogenic and analgesic effect of the bradykinin antagonist, bradyzide (BDZ) and the opioidergic analgesic, morphine (Mor) against inflammatory hyperalgesia induced by the dried latex (DL) of C. "
09/26/2014 - "Co-administration of selective antagonists of bradykinin B1 (Des-Arg(8)-Leu(9)-BK (DALBK)) or B2 receptors (bradyzide), β1 (atenolol) or β2 adrenoceptors (ICI 118,551), or local pre-treatment with the cyclooxygenase inhibitor indomethacin or the nonspecific selectin inhibitor fucoidan each significantly reduced BzATP-induced mechanical hyperalgesia in the rat hind paw. "
|2.||Hypotension (Low Blood Pressure)
01/01/2000 - "Bradyzide is orally available and blocks bradykinin-induced hypotension and plasma extravasation. "
01/01/2011 - "Further, blockade of B2R with bradyzide (2 mg/kg, intraperitoneally) abrogated the enhanced hypotensive effect of enalapril in ethanol-fed rats but had no effect on enalapril-evoked hypotension in control rats. "
10/01/2010 - "Using both contaminated heparin products and the synthetically produced derivative, the authors have shown that the OSCS produces a dose-dependent hypotension in both pigs and rats and that the response in rats can be abrogated with bradyzide, a rodent-selective B(2) bradykinin receptor antagonist. "
|2.||Morphine (MS Contin)
|4.||Bradykinin Receptors (Bradykinin Receptor)
|5.||Adrenergic Receptors (Adrenergic Receptor)
|6.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)